About Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.
|
|
|
11-50 employees
View all Bridge Biotherapeutics, Inc. employees
|
|
Biotechnology Research
|
|
58, Pangyo-ro 255 beon-gil, Bundang-gu, Suite 303, Seongnam-si, Gyeung-gi do 13486, KR
|
|
2015
|
Bridge Biotherapeutics, Inc. Alternatives
Frequently Asked Questions about Bridge Biotherapeutics, Inc.
The decision makers in Bridge Biotherapeutics, Inc. are Eun Young Park, Hyung Eun Kim, James Jungkue Lee, etc. Click to Find Bridge Biotherapeutics, Inc. decision makers emails.
Bridge Biotherapeutics, Inc. Staff Directory
Search Bridge Biotherapeutics, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
